title: [Systemic enzyme therapy in chronic glomerulonephritis].
abstract: OBJECTIVE
  To try polyenzyme drug vobenzim in chronic glomerulonephritis (CGN).
  
  
  METHODS
  174 CGN patients were randomized into 2 groups. The study group of 39 patients received conventional pathogenetic treatment plus vobenzim (initial dose 18-24, maintenance 12-15 dragees a day). Control group of 135 patients were given only pathogenetic therapy. 67 patients appeared ineligible.
  
  
  RESULTS
  3-6 months after the treatment the response was seen in 61.5% patients of the study and 17.8% patients of the control group. Side effects of vobenzim in CGN treatment were absent.
  
  
  CONCLUSIONS
  Enzyme therapy with vobenzim in CGN is safe and effective.
authors.forename: O V
authors.initials: OV
authors.lastname: Siniachenko
authors.forename: V N
authors.initials: VN
authors.lastname: Kovalenko
authors.forename: I V
authors.initials: IV
authors.lastname: Mukhin
authors.forename: G A
authors.initials: GA
authors.lastname: Ignatenko
authors.forename: A I
authors.initials: AI
authors.lastname: Terzov
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D002908:Chronic Disease; D005260:Female; D005921:Glomerulonephritis / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010447:Peptide Hydrolases / Q000008:administration & dosage / Q000627:therapeutic use*; D012449:Safety; D016896:Treatment Outcome
chemical_list: D010447:Peptide Hydrolases